Literature DB >> 17356196

Cerebral correlates of hyponatremia.

Barnett R Nathan1.   

Abstract

Hyponatremia, defined as a serum sodium concentration ([Na+]) less than 135 mEq/L, is commonly caused by elevated levels of the hormone arginine vasopressin (AVP), which causes water retention. The principal organ affected by disease-related morbidity is the brain. The neurologic complications associated with hyponatremia are attributable to cerebral edema and increased intracranial pressure, caused by the osmotically driven movement of water from the extracellular compartment into brain cells. Although neurologic symptoms induced by hyponatremia are limited by an adaptive brain mechanism known as "regulatory volume decrease," an overly rapid correction of serum [Na+] before the reversal of this adaptive response can also produce neurologic damage. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a frequent cause of hyponatremia related to central nervous system disorders, neurosurgery, or the use of psychoactive drugs. Fluid restriction is the standard of care for patients with SIADH who are asymptomatic or who have only mild symptoms, but patients with severe or symptomatic hyponatremia require more aggressive therapy. Infusion of hypertonic saline is the usual approach to the treatment of symptomatic hyponatremia, but patients require frequent monitoring. Pharmacologic agents such as demeclocycline and lithium may be effective in some patients but are associated with undesirable adverse events. The AVPreceptor antagonists are a new therapeutic class for the treatment of hyponatremia. The first agent in this class approved for the treatment of euvolemic hyponatremia in hospitalized patients is conivaptan. Two other agents, tolvaptan and lixivaptan, are being evaluated in patients with euvolemic and hypervolemic hyponatremia. The AVP-receptor antagonists block the effects of elevated AVP and promote aquaresis, the electrolyte-sparing excretion of water, resulting in the correction of serum [Na+]. These agents may also have intrinsic neuroprotective effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356196     DOI: 10.1385/NCC:6:1:72

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  43 in total

Review 1.  The pathophysiology and treatment of hyponatraemic encephalopathy: an update.

Authors:  Michael L Moritz; J Carlos Ayus
Journal:  Nephrol Dial Transplant       Date:  2003-12       Impact factor: 5.992

Review 2.  Mechanisms counteracting swelling in brain cells during hyponatremia.

Authors:  Herminia Pasantes-Morales; Rodrigo Franco; Benito Ordaz; Lenin D Ochoa
Journal:  Arch Med Res       Date:  2002 May-Jun       Impact factor: 2.235

Review 3.  Control of brain volume during hyperosmolar and hypoosmolar conditions.

Authors:  S R Gullans; J G Verbalis
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

Review 4.  A review of disorders of water homeostasis in psychiatric patients.

Authors:  A T Riggs; M W Dysken; S W Kim; J A Opsahl
Journal:  Psychosomatics       Date:  1991       Impact factor: 2.386

Review 5.  Differential diagnosis and treatment of hyponatremia following pituitary surgery.

Authors:  L A Casulari; K N Costa; R C R Albuquerque; L A Naves; K Suzuki; L Domingues
Journal:  J Neurosurg Sci       Date:  2004-03       Impact factor: 2.279

Review 6.  Vasopressin V2 receptor antagonists.

Authors:  J G Verbalis
Journal:  J Mol Endocrinol       Date:  2002-08       Impact factor: 5.098

Review 7.  Treatment of symptomatic hyponatremia.

Authors:  Guy Decaux; Alain Soupart
Journal:  Am J Med Sci       Date:  2003-07       Impact factor: 2.378

8.  Age and gender as risk factors for hyponatremia and hypernatremia.

Authors:  Robert C Hawkins
Journal:  Clin Chim Acta       Date:  2003-11       Impact factor: 3.786

Review 9.  Management of sodium abnormalities in patients with CNS disease.

Authors:  M N Diringer
Journal:  Clin Neuropharmacol       Date:  1992-12       Impact factor: 1.592

10.  A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.

Authors:  Florence Wong; Andres T Blei; Laurence M Blendis; Paul J Thuluvath
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  14 in total

1.  Non-peptide arginine-vasopressin antagonists (vaptans) for the treatment of hyponatremia in neurocritical care: a new alternative?

Authors:  Jeremy D Fields; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-05-08       Impact factor: 3.210

2.  A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury.

Authors:  Rajat Dhar; Theresa Murphy-Human
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

Review 3.  Sodium and fluid management in acute brain injury.

Authors:  Wendy L Wright
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

4.  Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.

Authors:  Andrew M Naidech; James Paparello; Storm M Liebling; Storm M Leibling; Sarice L Bassin; Kimberly Levasseur; Mark J Alberts; Richard A Bernstein; Kenji Muro
Journal:  Neurocrit Care       Date:  2010-08       Impact factor: 3.210

Review 5.  Impact of perioperative hyponatremia in children: A narrative review.

Authors:  Cheme Andersen; Arash Afshari
Journal:  World J Crit Care Med       Date:  2014-11-04

6.  Conivaptan for hyponatremia in the neurocritical care unit.

Authors:  Wendy L Wright; William H Asbury; Jane L Gilmore; Owen B Samuels
Journal:  Neurocrit Care       Date:  2008-11-12       Impact factor: 3.210

7.  Intracranial hypertension secondary to psychogenic polydipsia.

Authors:  Vanessa M Gleason; Niels D Martin
Journal:  J Emerg Trauma Shock       Date:  2012-04

Review 8.  The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular Diseases.

Authors:  Tanja Vukićević; Maike Schulz; Dörte Faust; Enno Klussmann
Journal:  Front Pharmacol       Date:  2016-02-11       Impact factor: 5.810

9.  Acute correction of hyponatremia secondary to psychogenic polydipsia.

Authors:  Coridon J Quinn; Uroghupatei P Iyegha; Greg J Beilman; Frank B Cerra
Journal:  Am J Case Rep       Date:  2012-05-17

10.  Occult pneumonia: an unusual but perilous entity presenting with severe malnutrition and dehydrating diarrhoea.

Authors:  Mohammod J Chisti; Mohammed A Salam; Mark A C Pietroni
Journal:  J Health Popul Nutr       Date:  2009-12       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.